TITLE

Pfizer, UCL form AMD collaboration

PUB. DATE
June 2009
SOURCE
Ophthalmology Times;6/15/2009, Vol. 34 Issue 12, p6
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the license agreement between Pfizer Inc.'s Regenerative Medicine and the University College London (UCL) in developing cell-based therapies for wet and dry age-related macular degeneration. According to Pfizer Chief Regenerative Medicine Ruth McKernan, the agreement signifies its reliance to UCL as an expert in stem cell ophthalmology. She added that the collaboration will increase their understanding about stem cell therapy which will advance technology development.
ACCESSION #
42226673

 

Related Articles

  • Ruth McKernan.  // Nature Reviews Drug Discovery;Mar2009, Vol. 8 Issue 3, p188 

    An interview with Dr. Ruth McKernan, the chief scientific officer of Pfizer Regenerative Medicine of Cambridge, England, is presented. When asked about the utilization of stem-cell-based technologies, she says that Pfizer has been using stem cells for almost 12 years in the discovery of drugs....

  • Pfizer's $100 million stem cell stake. Siva, Nayanah // Nature Biotechnology;Jan2009, Vol. 27 Issue 1, p10 

    The article states that the pharmaceutical company Pfizer has begun an independent research unit that focuses on developing new medicines from stem cells known as Pfizer Regenerative Medicine. One group located in Great Britain will be concerned with neural and sensory disorders, while another...

  • Pfizer and UCL join forces in stem cell development deal.  // Optometry Today;5/8/2009, Vol. 49 Issue 9, p13 

    The article reports on the partnership formed by scientists at University College London with Pfizer for the development of stem cell-based therapies for ophthalmic conditions. Under the terms of the agreement, the drugs company will provide funding to the University, enabling researchers to...

  • Early Lineage Adult Regenerative Cells Offer Promising New Cell-based Therapy. Ritter, Amy // BioPharm International;Apr2011, Vol. 24 Issue 4, p10 

    The article offers information on the cell-based therapy provided by early lineage adult (ELLA) regenerative cells, developed by Parcell Laboratories of Massachusetts.

  • Clinical Trials in Retinal Dystrophies. Grob, Seanna R.; Finn, Avni; Papakostas, Thanos D.; Eliott, Dean // Middle East African Journal of Ophthalmology;Jan-Mar2016, Vol. 23 Issue 1, p49 

    Research development is burgeoning for genetic and cellular therapy for retinal dystrophies. These dystrophies are the focus of many research efforts due to the unique biology and accessibility of the eye, the transformative advances in ocular imaging technology that allows for in vivo...

  • Researchers Progress Toward Eye Drop for Retinal Disease.  // Review of Ophthalmology;Apr2014, Vol. 21 Issue 4, p3 

    The article reviews a clinical study concerning age-related macular degeneration (AMD) conducted by scientists at the University College London led by Professor Francesca Cordeiro. According to the research, drugs used to treat blinding disorders could be successfully administered by eye drops...

  • Coalition aims to accelerate translation of cell therapies. Sinha, Gunjan // Nature Biotechnology;Jul2012, Vol. 30 Issue 7, p573 

    The article reports that spokespersons of six translational medicine centers working on cell based therapies met in Berlin, Germany to initiate the Regenerative Medicine Coalition (RMC). Frank-Roman Lauter, head of business development at Berlin-Brandenburg Center for RegenerativeTherapies in...

  • ACT Announces First Stargardt Patient Treated With Higher Dosage of Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells.  // Biomedical Market Newsletter;7/19/2012, Vol. 21, p1 

    The article informs that Advanced Cell Technology Inc. will be treating its 4th patient with Stargardt's Macular Dystrophy with the help of embryonic stem cell-derived retinal pigment epithelial cells. It further informs that the surgery was performed at Wills Eye Institute in Philadelphia,...

  • Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Lee, Andrew S; Tang, Chad; Rao, Mahendra S; Weissman, Irving L; Wu, Joseph C // Nature Medicine;Aug2013, Vol. 19 Issue 8, p998 

    Human pluripotent stem cells (PSCs) are a leading candidate for cell-based therapies because of their capacity for unlimited self renewal and pluripotent differentiation. These advances have recently culminated in the first-in-human PSC clinical trials by Geron, Advanced Cell Technology and the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics